Severe Insulin Resistance in Patients With Type 2 Diabetes: Mechanisms Behind Insulin Resistance.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 8
- 主要终点
- Insulin sensitivity
研究概览
简要总结
The purpose of the study is to investigate some of the mechanisms behind severe insulin resistance and to determine the dose response to insulin in patients with type 2 diabetes mellitus.
详细描述
Overnutrition and obesity are pivotal to the metabolic syndrome and diabetes. The sedentary lifestyle and overly rich nutrition are predominant in Western societies and result in obesity, insulin resistance and type 2 diabetes mellitus. According to the WHO an escalating global epidemic of overweight and obesity is sweeping the globe and the prevalence of type 2 diabetes mellitus rises in parallel at the same alarming rate. It is likely that inherited insulin resistance relates to subtle mutations in many metabolic genes. It is still unclear whether such abnormalities lead to different proteomic patterns in target tissues (muscle and fat) and how intracellular hormone signaling is affected. Some patients with type 2 diabetes mellitus have severe insulin resistance with insulin requirements of more than 100 units/day and are still not optimally controlled. Our aim of this study is to examine the mechanisms behind severe insulin resistance and to elucidate how intracellular hormone signaling is affected, especially in relation to proteomics. Moreover we wish to determine the dose response to insulin in patients with type 2 diabetes mellitus with severe insulin resistance in order to see if there is a measurable effect on blood glucose at high insulin doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 25 Years 至 75 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 25-75 years old
- •BMI between 25 and 42
排除标准
- •Severe diseases
研究组 & 干预措施
L1
Actrapid infusion, 0.5 mU/kg/min.
干预措施: Actrapid (human insulin) (Drug)
L2
Actrapid infusion 1.5 mU/kg/min
干预措施: Actrapid (human insulin) (Drug)
H1
Actrapid infusion 3.0 mU/kg/min
干预措施: Actrapid (human insulin) (Drug)
H2
Actrapid infusion 5.0 mU/kg/min
干预措施: Actrapid (human insulin) (Drug)
结局指标
主要结局
Insulin sensitivity
时间窗: 8 hours
次要结局
- Changes in insulin signaling proteins?(1 month)
